Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2,058 DKK | +1.58% | +2.56% | -5.29% |
05-15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
05-15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.29% | 19.07B | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.79% | 22.28B | |
-11.90% | 22.41B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B | |
+271.25% | 7.62B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance